These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 26452024)

  • 1. Biomarker-based prognostic stratification of young adult glioblastoma.
    Zhang RQ; Shi Z; Chen H; Chung NY; Yin Z; Li KK; Chan DT; Poon WS; Wu J; Zhou L; Chan AK; Mao Y; Ng HK
    Oncotarget; 2016 Jan; 7(4):5030-41. PubMed ID: 26452024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebellar glioblastoma: a clinical series with contemporary molecular analysis.
    Hong B; Banan R; Christians A; Nakamura M; Lalk M; Lehmann U; Hartmann C; Krauss JK
    Acta Neurochir (Wien); 2018 Nov; 160(11):2237-2248. PubMed ID: 30203362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric low-grade gliomas can be molecularly stratified for risk.
    Yang RR; Aibaidula A; Wang WW; Chan AK; Shi ZF; Zhang ZY; Chan DTM; Poon WS; Liu XZ; Li WC; Zhang RQ; Li YX; Chung NY; Chen H; Wu J; Zhou L; Li KK; Ng HK
    Acta Neuropathol; 2018 Oct; 136(4):641-655. PubMed ID: 29948154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. H3F3A K27M mutations in thalamic gliomas from young adult patients.
    Aihara K; Mukasa A; Gotoh K; Saito K; Nagae G; Tsuji S; Tatsuno K; Yamamoto S; Takayanagi S; Narita Y; Shibui S; Aburatani H; Saito N
    Neuro Oncol; 2014 Jan; 16(1):140-6. PubMed ID: 24285547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers.
    Korshunov A; Ryzhova M; Hovestadt V; Bender S; Sturm D; Capper D; Meyer J; Schrimpf D; Kool M; Northcott PA; Zheludkova O; Milde T; Witt O; Kulozik AE; Reifenberger G; Jabado N; Perry A; Lichter P; von Deimling A; Pfister SM; Jones DT
    Acta Neuropathol; 2015 May; 129(5):669-78. PubMed ID: 25752754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas.
    Nencha U; Rahimian A; Giry M; Sechi A; Mokhtari K; Polivka M; Schmitt Y; Di Stefano AL; Alentorn A; Labussière M; Sanson M
    J Neurooncol; 2016 Feb; 126(3):441-6. PubMed ID: 26608520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
    Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
    Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A sensitive and specific histopathologic prognostic marker for H3F3A K27M mutant pediatric glioblastomas.
    Venneti S; Santi M; Felicella MM; Yarilin D; Phillips JJ; Sullivan LM; Martinez D; Perry A; Lewis PW; Thompson CB; Judkins AR
    Acta Neuropathol; 2014 Nov; 128(5):743-53. PubMed ID: 25200322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas.
    Venneti S; Garimella MT; Sullivan LM; Martinez D; Huse JT; Heguy A; Santi M; Thompson CB; Judkins AR
    Brain Pathol; 2013 Sep; 23(5):558-64. PubMed ID: 23414300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. H3F3A K27M mutation in pediatric CNS tumors: a marker for diffuse high-grade astrocytomas.
    Gielen GH; Gessi M; Hammes J; Kramm CM; Waha A; Pietsch T
    Am J Clin Pathol; 2013 Mar; 139(3):345-9. PubMed ID: 23429371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma.
    Paulsson J; Lindh MB; Jarvius M; Puputti M; Nistér M; Nupponen NN; Paulus W; Söderberg O; Dresemann G; von Deimling A; Joensuu H; Ostman A; Hasselblatt M
    Int J Cancer; 2011 Apr; 128(8):1981-8. PubMed ID: 20589679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic signature and treatment of pediatric high-grade glioma.
    Guidi M; Giunti L; Buccoliero AM; Caporalini C; Censullo ML; Galli L; Genitori L; Sardi I
    Mol Clin Oncol; 2021 Apr; 14(4):70. PubMed ID: 33732456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A long-term survivor of pediatric midline glioma with H3F3A K27M and BRAF V600E double mutations.
    Nakano Y; Yamasaki K; Sakamoto H; Matsusaka Y; Kunihiro N; Fukushima H; Inoue T; Honda-Kitahara M; Hara J; Yoshida A; Ichimura K
    Brain Tumor Pathol; 2019 Oct; 36(4):162-168. PubMed ID: 31254135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TERT promoter mutations in primary and secondary glioblastomas.
    Nonoguchi N; Ohta T; Oh JE; Kim YH; Kleihues P; Ohgaki H
    Acta Neuropathol; 2013 Dec; 126(6):931-7. PubMed ID: 23955565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic features of small cell glioblastomas.
    Takeuchi H; Kitai R; Hosoda T; Yamada S; Hashimoto N; Kikuta K; Shimizu Y; Kimura H
    J Neurooncol; 2016 Apr; 127(2):337-44. PubMed ID: 26725094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Isocitrate dehydrogenase type I mutation as a prognostic factor in glioblastoma and a literature review].
    de Quintana-Schmidt C; Alvarez-Holzapfel MJ; Nomdedeu-Guinot J; Bague-Rosell S; Gallego-Rubio O; Leidinger A; Salgado-Lopez L; Molet-Teixidó J
    Neurocirugia (Astur); 2015; 26(6):276-83. PubMed ID: 26194445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.
    Nobusawa S; Watanabe T; Kleihues P; Ohgaki H
    Clin Cancer Res; 2009 Oct; 15(19):6002-7. PubMed ID: 19755387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of an epithelioid glioblastoma with the BRAF V600E mutation colocalized with BRAF intact low-grade diffuse astrocytoma.
    Kuroda J; Nobusawa S; Nakamura H; Yokoo H; Ueda R; Makino K; Yano S; Kuratsu J
    Neuropathology; 2016 Apr; 36(2):181-6. PubMed ID: 26375727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis.
    Korshunov A; Chavez L; Sharma T; Ryzhova M; Schrimpf D; Stichel D; Capper D; Sturm D; Kool M; Habel A; Kleinschmidt-DeMasters BK; Rosenblum M; Absalyamova O; Golanov A; Lichter P; Pfister SM; Jones DTW; Perry A; von Deimling A
    Brain Pathol; 2018 Sep; 28(5):656-662. PubMed ID: 28990704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.